Washington, DC (November 8, 2019) -- The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2019 November 5-November 10 at the Walter E. Washington Convention Center in Washington, DC.
Mycophenolate Mofetil vs. Azathioprine in Kidney Transplant Recipients on Steroid-Free, Low-Dose Cyclosporine Immunosuppression: The ATHENA Trial
A Phase 2 Randomized, Controlled Study of Obinutuzumab with Mycophenolate and Corticosteroids in Proliferative Lupus Nephritis
Efficacy and safety of difelikefalin in patients undergoing hemodialysis with pruritus: Results from a phase 3, randomized, controlled study (KALM-1)
Effect of Angiotensin-Neprilysin Inhibition on Renal Outcomes in Heart Failure with Preserved Ejection Fraction
Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial
Preventing Early Renal Loss in Diabetes (PERL) Study: Outcome of a 3-Year Trial of Serum Uric Acid Reduction with Allopurinol
The Dapagliflozin in Heart Failure with Reduced Ejection Fraction Trial (DAPA-HF): Outcomes in Patients with CKD and Effects on Renal Function
###
ASN Kidney Week 2019, the largest nephrology meeting of its kind, will provide a forum for more than 13,000 professionals to discuss the latest findings in kidney health research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2019 will take place November 5 - November 10 in Washington, DC.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit http://www.asn-online.org or contact the society at 202-640-4660.